Solomon, S. D., Zile, M., Pieske, B., Voors, A. A., Shah, A., Kraigher-Krainer, E., … McMurray, J. J. V. (2012). The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction: A Phase II Randomised-Controlled Trial. Journal of Cardiac Failure, 18(11), 883–883. https://doi.org/10.1016/j.cardfail.2012.10.006

Solomon, Scott D., Michael Zile, Burkert Pieske, Adriaan A. Voors, Amil Shah, Elisabeth Kraigher-Krainer, Victor Shi, et al. “The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction: A Phase II Randomised-Controlled Trial.” Journal of Cardiac Failure 18, no. 11 (November 2012): 883–883. https://doi.org/10.1016/j.cardfail.2012.10.006.

Solomon SD, Zile M, Pieske B, Voors AA, Shah A, Kraigher-Krainer E, et al. The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction: A Phase II Randomised-Controlled Trial. Journal of Cardiac Failure. 2012 Nov;18(11):883–883.

Solomon, Scott D., et al. “The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction: A Phase II Randomised-Controlled Trial.” Journal of Cardiac Failure, vol. 18, no. 11, Elsevier BV, Nov. 2012, pp. 883–883. Crossref, doi:10.1016/j.cardfail.2012.10.006.

Solomon SD, Zile M, Pieske B, Voors AA, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJV. The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction: A Phase II Randomised-Controlled Trial. Journal of Cardiac Failure. Elsevier BV; 2012 Nov;18(11):883–883.